Bluebird bio Inc
NASDAQ:BLUE
| Market Cap (Intraday) | 785.28M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.62 |
| 50-Day MA | $6.69 |
| 200-Day MA | $5.29 |
Bluebird bio Inc Stock, NASDAQ:BLUE
60 Binney Street, 455 Grand Union Boulevard, Somerville, Massachusetts 02145
United States of America
Phone: +1.339.499.9300
Number of Employees: 518
Description
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.